恩格列净提升抗利尿不当综合征患者血钠的随机试验
这项双盲随机试验纳入88例住院SIAD相关低钠血症(<130 mmol/L)患者,在限液<1000 ml/24 h基础上加用恩格列净或安慰剂4天。恩格列净组血钠中位升高10 mmol/L,安慰剂组7 mmol/L(P=0.04),治疗耐受良好,无低血糖或低血压事件。
要点
- 限液基础上加用恩格列净4天可显著提升SIAD患者血钠。
- 严重低钠(<125 mmol/L)和基线低渗者应答可能性更高。
- 恩格列净组未观察到低血糖或低血压事件。
核心结论
- 在限液治疗的住院SIAD患者中,恩格列净组血钠升高幅度大于安慰剂组。
研究设计与样本
- 双盲随机试验,2016年9月至2019年1月在巴塞尔大学医院招募88例SIAD相关低钠血症(<130 mmol/L)住院患者。
- 患者随机接受每日一次口服恩格列净或安慰剂共4天,均联合限液<1000 ml/24 h。
- 87例完成试验,恩格列净组43例(49%),安慰剂组44例(51%)。
主要发现
- 恩格列净组血钠中位升高10 mmol/L,安慰剂组升高7 mmol/L(P=0.04)。
- 基线血钠中位数恩格列净组125.5 mmol/L,安慰剂组126 mmol/L。
- 严重低钠血症(<125 mmol/L)和较低基线渗透压水平增加恩格列净治疗应答可能性。
- 治疗耐受良好,恩格列净组无低血糖或低血压事件。
临床怎么用
- 对SIAD相关低钠血症住院患者,可考虑在限液基础上加用恩格列净以提升血钠。
- 严重低钠(<125 mmol/L)或基线低渗患者可能更受益于恩格列净治疗。
局限性
- 研究仅纳入住院患者,样本量有限(88例),随访仅4天。
- 原文未报告长期结局、剂量细节及更多安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options to address the hyponatremia induced by the syndrome of inappropriate antidiuresis (SIAD) are inadequate. The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion and therefore, might offer a novel treatment option for SIAD. METHODS: In this double-blind, randomized trial, we recruited 88 hospitalized patients with SIAD-induced hyponatremia <130 mmol/L at the University Hospital Basel from September 2016 until January 2019 and assigned patients to receive, in addition to standard fluid restriction of <1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 days. The primary end point was the absolute change in plasma sodium concentration after 4 days of treatment. Secondary end points included predisposing factors for treatment response and safety of the intervention. RESULTS: Of the 87 patients who completed the trial, 43 (49%) received treatment with empagliflozin, and 44 (51%) received placebo. Baseline plasma sodium concentrations were similar for the two groups (median 125.5 mmol/L for the empaflozin group and median 126 mmol/L for the placebo group). Patients treated with empagliflozin had a significantly higher increase of median plasma sodium concentration compared with those receiving placebo (10 versus 7 mmol/L, respectively; P=0.04). Profound hyponatremia (<125 mmol/L) and lower baseline osmolality levels increased the likelihood of response to treatment with empagliflozin. Treatment was well tolerated, and no events of hypoglycemia or hypotension occurred among those receiving empagliflozin. CONCLUSIONS: Among hospitalized patients with SIAD treated with fluid restriction, those who received empagliflozin had a larger increase in plasma sodium levels compared with those who received placebo. This finding indicates that empagliflozin warrants further study as a treatment for the disorder.
引用
- Refardt J, Imber C, Sailer CO, et al. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. J Am Soc Nephrol. 2020. PMID: 32019783. doi:10.1681/ASN.2019090944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。